biotechnology

Biotech

How swallowing a star might keep you from missing a dose of medicine

By Jonathan Saltzman — Boston Globe

JPM 2020 Lombard St
Adam's Take

The truth about JPM: Less is more

By Adam Feuerstein

Play
The Readout LOUD

Listen: A J.P. Morgan recap, a plan to bust pharma monopolies, and a website for cancer patients

By Rebecca Robbins, Damian Garde, and Adam Feuerstein

Brain neurons
Biotech

A venture firm warms to funding neuroscience

By Matthew Herper

STAT SPOTLIGHT
Biotech

Startup Spotlight: With a different method for gene therapy, Generation Bio eyes an IPO

By Kate Sheridan

Fatty Liver
Biotech

On the cusp of FDA approval for its NASH drug, Intercept’s CEO talks payers, pruritis, and price

By Adam Feuerstein

Patrick Soon-Shiong
Biotech

After a single patient drives a big stock surge, Patrick Soon-Shiong makes his case to investors

By Rebecca Robbins

JPM 2020 Lombard St
Adam's Take

All talk, no M&A makes for a down JPM Day

By Adam Feuerstein

AstraZeneca signage
Biotech

AstraZeneca fish oil drug fails, leaving Amarin as last drug standing

By Matthew Herper

Biotech

Agios CEO forecasts ‘line of sight’ to more approved drugs and profits

By Adam Feuerstein

Biotech

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

By Adam Feuerstein

Lego DNA
First Opinion

Welcome to the bioengineering culture clash

By Vijay Pande

Play
The Readout LOUD

Listen: Biohacker Josiah Zayner on getting canceled, good news in cancer, and a long road in Ebola

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

JPM 20 years illustration
Biotech

The ghosts of JPMs past: How 20 years of deals, scandal, and science have shaped health care

By Matthew Herper, Damian Garde, Rebecca Robbins, and Adam Feuerstein

Adam's Take

Two days into the ‘real’ start of 2020 and all those expected biotech buyouts are still MIA

By Adam Feuerstein

Knee replacement
Biotech

Anika Therapeutics acquires two companies for their joint-replacement products

By Jonathan Saltzman — Boston Globe

Shattered blood cell
Biotech

Apellis Pharmaceuticals’ drug candidate outperforms Alexion’s Soliris in a clinical trial comparing the two

By Kate Sheridan

Adam's Take

Biotech 2020 preview: Takeover targets, notable drug launches, and genome editing readouts

By Adam Feuerstein

Scorecard
Biotech

The biotech scorecard for the first quarter: 14 stock-moving events to watch

By Adam Feuerstein

2010- 2019 Medicine
Biotech

STAT’s guide to the most important, beneficial drugs approved in the past decade

By Adam Feuerstein and Matthew Herper

Biotech graveyard
Biotech

Crash and burn: The four biggest biopharma failures of 2019

By Kate Sheridan

2019 to Watch Biotech
Biotech

3 trends in biotech to watch in 2020

By Damian Garde

Cambridge: Sarepta
Biotech

Sarepta sells international rights to Duchenne gene therapy to Roche

By Adam Feuerstein

CRISPR-edited pigs
In the Lab

Creating Pig3.0, the world’s most CRISPR’d animal, raises hopes of transplantable organs

By Sharon Begley

Good/Bad CEO 2017
Adam's Take

Maraganore victorious in best biopharma CEO tally; Vounatsos tops worst list

By Adam Feuerstein

Play
The Readout LOUD

Listen: The decade in breakthrough drugs, the year in bad CEOing, and the viruses that cure disease

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

ASH19 sickle cell disease blood sample
Biotech

In a shift toward venture capital fundraising, FORMA Therapeutics brings in $100 million 

By Kate Sheridan

ASH19 Gene Therapy Sickle Cell
Biotech

Research pact between Syros Pharma, Global Blood seeks new drugs to treat sickle cell disease

By Adam Feuerstein

Bone marrow transplant
Biotech

Cutting-edge therapies promise one-time cures, but not without risk. Can biotech make them safer?

By Adam Feuerstein

Your daily dose of news in health and medicine

Privacy Policy